HB8032, the Facilitating Access to Innovation in Cancer Care Act (FAIC Act), would change how Medicare pays for certain cancer drugs and biologics furnished in hospital outpatient settings. Beginning in 2026, the bill requires separate payment for qualifying cancer treatments instead of allowing their costs to be bundled, or “packaged,” into broader outpatient department service payments under the Medicare hospital outpatient prospective payment system.
The bill applies only to “specified cancer treatments,” defined as FDA-approved drugs or biologics for cancer detection or treatment approved on or after January 1, 2008, that do not already receive transitional pass-through payments and that would otherwise be packaged into outpatient service payments. For these products, Medicare would pay based on average sales price when available, or wholesale acquisition cost, or otherwise mean unit cost from hospital claims data. The bill sets an initial 2026 threshold of $350 in estimated mean per-day product cost, with later years indexed to the outpatient department fee schedule increase factor. It also includes a budget-neutrality requirement directing the Secretary of Health and Human Services to make offsetting adjustments so overall Medicare spending under the outpatient payment system does not increase because of the new separate-payment rule.
In practical terms, the bill would affect Medicare reimbursement policy, hospital outpatient departments, oncology providers, drug manufacturers, and Medicare beneficiaries receiving cancer care in hospital outpatient settings. By carving certain cancer therapies out of bundled payment rates, the measure is intended to improve payment accuracy and preserve access to newer cancer treatments that might otherwise be underpaid when included in a broader outpatient payment bundle. The bill amends section 1833(t)(16) of the Social Security Act, which governs Medicare outpatient prospective payment rules.
The general sentiment reflected by the bill’s introduction is supportive of expanding access to innovative cancer care and ensuring more equitable Medicare payment for high-cost oncology treatments. The bill was introduced by Representatives Dunn and Soto and referred to the House Committees on Energy and Commerce and Ways and Means, but no committee debate, votes, or recorded opposition are included in the provided materials. As a result, there is no documented floor or committee sentiment beyond the bill’s stated purpose.
The main point of potential contention is the policy tradeoff between improving reimbursement for cancer drugs and maintaining Medicare budget neutrality. Supporters are likely to view the bill as necessary to prevent access barriers and underpayment for newer therapies, while critics could question whether separate payment for more drugs will shift costs elsewhere in the outpatient system or create incentives for higher spending. The threshold, product definitions, and use of pricing benchmarks such as average sales price and wholesale acquisition cost are also likely areas of technical scrutiny.
The bill would amend the Social Security Act’s Medicare outpatient prospective payment provisions to require separate reimbursement for certain qualifying cancer drugs and biologics rather than packaging their costs into broader outpatient department payments. This would directly affect Medicare payment methodology, hospital outpatient billing, and reimbursement for oncology products, while preserving budget neutrality through offsetting payment adjustments elsewhere in the system.
The available context suggests a generally favorable, access-oriented intent: the bill is framed as a way to protect Medicare beneficiary access to innovative cancer treatments and ensure fair payment for providers and manufacturers. No votes or committee remarks are provided, so there is no recorded opposition or bipartisan debate in the supplied materials, only the bill’s pro-access policy rationale.
The likely contention centers on whether Medicare should carve out high-cost cancer therapies from bundled outpatient payments and how to do so without increasing overall program spending. Supporters would emphasize beneficiary access, accurate payment, and support for innovation; skeptics may focus on budget neutrality, the administrative complexity of defining qualifying treatments, and the possibility that separate payment could raise costs or distort outpatient payment incentives.